Stocktoria
Entera Bio Ltd. ENTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-28
Entera Bio Ltd. statistics & valuation
Market cap$80.3M
P / B6.1×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 0.0% | 5.0% | — | 24.6% | 34.7% |
| Operating margin | -27450.0% | -5295.6% | — | -9714.2% | -2139.6% |
| Net margin | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% |
| FCF margin | -17802.4% | -3768.5% | — | -9362.7% | -1590.2% |
| Return on assets | -71.5% | -101.6% | -75.6% | -99.6% | -46.9% |
| Return on equity | -87.3% | -118.1% | -85.6% | -111.2% | -54.0% |
| Current ratio | 6.94 | 7.63 | 10.32 | 9.58 | 8.01 |
| Revenue growth | -76.8% | — | -100.0% | -76.5% | 56.4% |
Source: SEC EDGAR filings · CIK 0001638097 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.